Pay attention to the selective lateral pelvic lymph node dissection in mid-low rectal cancer.
- Author:
Wenjian MENG
;
Ziqiang WANG
1
Author Information
1. Department of Gastrointestinal Surgery, West China Hospital, Chengdu 610041, China. wangzqzyh@163.com.
- Publication Type:Journal Article
- MeSH:
Chemoradiotherapy;
Digestive System Surgical Procedures;
trends;
Humans;
Lymph Node Excision;
methods;
trends;
Lymphatic Metastasis;
Neoadjuvant Therapy;
Neoplasm Recurrence, Local;
prevention & control;
Pelvis;
surgery;
Prognosis;
Rectal Neoplasms;
surgery;
therapy
- From:
Chinese Journal of Gastrointestinal Surgery
2017;20(3):258-262
- CountryChina
- Language:Chinese
-
Abstract:
Lateral pelvic lymph node metastasis is an important metastatic mode and a major cause of locoregional recurrence of mid-low rectal cancer. Recently, there is an East-West discrepancy in regard to the diagnosis, clinical significance, treatment and prognosis of lateral pelvic lymph node metastasis. In the West, lateral nodal involvement may represent systemic disease and preoperative chemoradiotherapy can sterilize clinically suspected lateral nodes. Thus, in many Western countries, the standard therapy for lower rectal cancer is total mesorectal excision with chemoradiotherapy, and pelvic sidewall dissection is rarely performed. In the East, and Japan in particular, however, there is a positive attitude in regard to lateral pelvic lymph node dissection (LPND). They consider that lateral pelvic lymph node metastasis is as regional metastasis, and the clinically suspected lateral nodes can not be removed by neoadjuvant chemoradiotherapy. The selective LPND after neoadjuvant chemoradiotherapy may be found to be promising treatment for the improvement of therapeutic benefits in these patients. Therefore, the large-scale prospective studies are urgently required to improve selection criteria for LPND and neoadjuvant treatment to prevent overtreatment in the near future. Selective LPND after neoadjuvant treatment based on modern imaging techniques is expected to reduce locoregional recurrence and improve long-term survival in patients with mid-low rectal cancer.
